In 2017, FDA approved the first CAR T cell therapy, CD19-targeted, used for the treatment of B cell acute lymphoblastic leukemia and acute lymphoblastic leukemia (ALL) (1). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.